Quick Answer
Sana Biotechnology, Inc. reported Diluted EPS of $0.96 per share (loss) for fiscal year 2025.
Sana Biotechnology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.96 | +17.2% |
| 2024 | -$1.16 | +20.5% |
| 2023 | -$1.46 | -2.1% |
| 2022 | -$1.43 | +33.2% |
| 2021 | -$2.14 | +90.2% |
| 2020 | -$21.92 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.16 | +36.0% | +59.0% |
| June 30, 2025 | -$0.39 | -85.7% | -85.7% |
| March 31, 2025 | -$0.21 | +57.1% | +16.0% |
| September 30, 2024 | -$0.25 | — | -19.0% |
| June 30, 2024 | -$0.21 | +64.4% | +57.1% |
| March 31, 2024 | -$0.49 | -14.0% | — |
| September 30, 2023 | $0.00 | +100.0% | +100.0% |
| June 30, 2023 | -$0.59 | -51.3% | -37.2% |
- Sana Biotechnology, Inc. showed an increase of +17.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Sana Biotechnology, Inc.’s diluted eps has grown by 95.6% (from $21.92 per share (loss) to $0.96 per share (loss)).
- The most recent figure is from Sana Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: